ReviewStem cells and development2017
Human Neural Stem Cell Therapy for Chronic Ischemic Stroke: Charting Progress from Laboratory to Patients.
Review in Stem cells and development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- [Research progress of different types of stem cells in treatment of ischemic stroke].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2021Pooled it
- Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2).Journal of neurology, neurosurgery, and psychiatry · 2020Trial
- Translational stem cell therapy for neurodegeneration and CNS trauma: a focused review.Molecular biology reports · 2026Review
- Selenized neural stem cell-derived exosomes: A neotype therapeutic agent for traumatic injuries of the central nervous system.Cell reports. Medicine · 2025Article
- Review
- Nanotechnology approaches to drug delivery for the treatment of ischemic stroke.Bioactive materials · 2025Review
- Immortalization of Mesenchymal Stem Cells for Application in Regenerative Medicine and Their Potential Risks of Tumorigenesis.International journal of molecular sciences · 2024Review
- Cell therapy for neurological disorders.Nature medicine · 2024Review
- The Relevance of Reperfusion Stroke Therapy for miR-9-3p and miR-9-5p Expression in Acute Stroke-A Preliminary Study.International journal of molecular sciences · 2024Article
- Adult Neurogenesis of the Medial Geniculate Body: In Vitro and Molecular Genetic Analyses Reflect the Neural Stem Cell Capacity of the Rat Auditory Thalamus over Time.International journal of molecular sciences · 2024Article
- Practical Use of Immortalized Cells in Medicine: Current Advances and Future Perspectives.International journal of molecular sciences · 2023Review
- Application of stem cells in regeneration medicine.MedComm · 2023Review
- Therapeutic Potential of Chinese Medicine for Endogenous Neurogenesis: A Promising Candidate for Stroke Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Methodological considerations in PISCES 3: a randomized, placebo-controlled study of intracerebral stem cells in subjects with disability following an ischemic stroke.Frontiers in stroke · 2023Article
- Artesunate regulates the proliferation and differentiation of neural stem cells by activating the JAK‑2/STAT‑3 signaling pathway in ischemic stroke.Experimental and therapeutic medicine · 2023Article
- Stem Cell- and Cell-Based Therapies for Ischemic Stroke.Bioengineering (Basel, Switzerland) · 2022Review
- Neural Stem Cells Therapy for Ischemic Stroke: Progress and Challenges.Translational stroke research · 2022Review
- Combination of stem cell therapy and acupuncture to treat ischemic stroke: a prospective review.Stem cell research & therapy · 2022Review
- Engineered cells as glioblastoma therapeutics.Cancer gene therapy · 2022Review
- The Beneficial Potential of Genetically Modified Stem Cells in the Treatment of Stroke: a Review.Stem cell reviews and reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic disability after stroke represents a major unmet neurologic need. ReNeuron's development of a human neural stem cell (hNSC) therapy for chronic disability after stroke is progressing through early clinical studies. A Phase I trial has recently been published, showing no safety concerns and some promising signs of efficacy. A single-arm Phase II multicenter trial in patients with stable upper-limb paresis has recently completed recruitment. The hNSCs administrated are from a manufactured, conditionally immortalized hNSC line (ReNeuron's CTX0E03 or CTX), generated with c-mycER
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.